Total equity of Indofarma FY 2019-2022
At the end of financial year 2022, PT Indofarma (Persero), Tbk recorded total equity of approximately 86.35 billion Indonesian rupiah, indicating a significant decrease compared to the previous year. The company is a subsidiary of PT Bio Farma (Persero), a state-owned pharmaceutical enterprise, and one of the leading companies in the pharmaceutical industry in Indonesia.